# Edgewise Therapeutics Reports Third Quarter 2026 Financial Results

- Source: PR Newswire M&A
- Published: 2026-11-04T21:01:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/edgewise-therapeutics-reports-third-quarter-2026-financial-results-302929509.html
- Canonical: https://groundlevelnews.com/story/edgewise-therapeutics-reports-third-quarter-2026-financial-results-cf1e49/

– Published the differentiated mechanism of action of EDG-7500 that targets the regulatory light chain – – Phase 3 trial for EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) on track to initiate by year-end 2026 – – Dosed first patient in Phase 2 EQUINOX-HFpEF...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire M&A._